The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Obesity Hypoventilation Syndrome Treatment Market Research Report 2025
Synopsis
Obesity hypoventilation syndrome is defined as alveolar hypoventilation while awake in an obese individual where there is no other cause of the hypoventilation (such as a sedating drug). Ninety percent of people with obesity hypoventilation syndrome (OHS) also have an associated obstructive sleep apnea.The mainstay of treatment in OHS is to provide breathing support, often through the use of continuous positive airway pressure (CPAP) or bilevel.
Global Obesity Hypoventilation Syndrome Treatment market is projected to reach US$ 1893.4 million in 2029, increasing from US$ 1280 million in 2022, with the CAGR of 5.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Obesity Hypoventilation Syndrome Treatment market research.
The global obesity hypoventilation syndrome (OHS) treatment market refers to the market for therapeutic interventions and management strategies aimed at addressing the symptoms and complications associated with obesity hypoventilation syndrome. OHS is a condition characterized by a combination of obesity, decreased lung function, and physiological impairment in respiratory control, leading to inadequate ventilation during sleep.
The market for OHS treatment is driven by several factors, including the increasing prevalence of obesity worldwide, rising awareness about the condition, and the growing understanding of its associated health risks. OHS can lead to serious complications such as cardiopulmonary disorders, hypertension, and metabolic abnormalities, necessitating effective treatment approaches.
The primary goal of OHS treatment is to improve respiratory function and alleviate symptoms of hypoventilation. Treatment options may include lifestyle modifications, such as weight loss programs and physical activity, as well as interventions to enhance respiratory function, such as positive airway pressure therapy and ventilatory support.
Geographically, North America currently dominates the global OHS treatment market, primarily due to the high prevalence of obesity and well-established healthcare infrastructure. Europe is another significant market, driven by factors such as increasing awareness, government initiatives to combat obesity, and the availability of advanced healthcare facilities.
Asia-Pacific is expected to witness substantial growth in the coming years, attributed to factors such as the rising prevalence of obesity, changing lifestyles, and increasing healthcare expenditure.
Key players in the global OHS treatment market include ResMed Inc., Philips Respironics, Fisher & Paykel Healthcare Ltd., GE Healthcare, and Medtronic PLC, among others. These companies focus on developing innovative treatment devices and solutions, conducting research studies, and collaborating with healthcare professionals to address the specific needs of OHS patients.
However, challenges in the OHS treatment market include the limited awareness among the general population and healthcare professionals, lack of standardized diagnostic criteria, and the need for further clinical evidence to support the efficacy of different treatment modalities.
In summary, the global obesity hypoventilation syndrome treatment market is driven by factors such as the prevalence of obesity, awareness about the condition’s associated health risks, and advancements in treatment options. North America currently leads the market, but Asia-Pacific is projected to witness significant growth. Key players in the market continue to invest in research and development to improve treatment outcomes and address the unmet needs of OHS patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Obesity Hypoventilation Syndrome Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Accord Healthcare Limited
Avet Pharmaceuticals Inc
Nostrum Laboratories Inc
Lannett Co Inc
Strides Pharma Science Limited
X Gen Pharmaceuticals Inc
ResMed
Koninklijke Philips NV
Hikma Pharmaceuticals
Lincare Holdings
Philips Respironics
Fisher & Paykel Healthcare Ltd
GE Healthcare
Medtronic PLC
Segment by Type
Oxygen Therapy
Non-invasive Mechanical Ventilation
Drug Therapy
Other
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Obesity Hypoventilation Syndrome Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Obesity hypoventilation syndrome is defined as alveolar hypoventilation while awake in an obese individual where there is no other cause of the hypoventilation (such as a sedating drug). Ninety percent of people with obesity hypoventilation syndrome (OHS) also have an associated obstructive sleep apnea.The mainstay of treatment in OHS is to provide breathing support, often through the use of continuous positive airway pressure (CPAP) or bilevel.
Global Obesity Hypoventilation Syndrome Treatment market is projected to reach US$ 1893.4 million in 2029, increasing from US$ 1280 million in 2022, with the CAGR of 5.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Obesity Hypoventilation Syndrome Treatment market research.
The global obesity hypoventilation syndrome (OHS) treatment market refers to the market for therapeutic interventions and management strategies aimed at addressing the symptoms and complications associated with obesity hypoventilation syndrome. OHS is a condition characterized by a combination of obesity, decreased lung function, and physiological impairment in respiratory control, leading to inadequate ventilation during sleep.
The market for OHS treatment is driven by several factors, including the increasing prevalence of obesity worldwide, rising awareness about the condition, and the growing understanding of its associated health risks. OHS can lead to serious complications such as cardiopulmonary disorders, hypertension, and metabolic abnormalities, necessitating effective treatment approaches.
The primary goal of OHS treatment is to improve respiratory function and alleviate symptoms of hypoventilation. Treatment options may include lifestyle modifications, such as weight loss programs and physical activity, as well as interventions to enhance respiratory function, such as positive airway pressure therapy and ventilatory support.
Geographically, North America currently dominates the global OHS treatment market, primarily due to the high prevalence of obesity and well-established healthcare infrastructure. Europe is another significant market, driven by factors such as increasing awareness, government initiatives to combat obesity, and the availability of advanced healthcare facilities.
Asia-Pacific is expected to witness substantial growth in the coming years, attributed to factors such as the rising prevalence of obesity, changing lifestyles, and increasing healthcare expenditure.
Key players in the global OHS treatment market include ResMed Inc., Philips Respironics, Fisher & Paykel Healthcare Ltd., GE Healthcare, and Medtronic PLC, among others. These companies focus on developing innovative treatment devices and solutions, conducting research studies, and collaborating with healthcare professionals to address the specific needs of OHS patients.
However, challenges in the OHS treatment market include the limited awareness among the general population and healthcare professionals, lack of standardized diagnostic criteria, and the need for further clinical evidence to support the efficacy of different treatment modalities.
In summary, the global obesity hypoventilation syndrome treatment market is driven by factors such as the prevalence of obesity, awareness about the condition’s associated health risks, and advancements in treatment options. North America currently leads the market, but Asia-Pacific is projected to witness significant growth. Key players in the market continue to invest in research and development to improve treatment outcomes and address the unmet needs of OHS patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Obesity Hypoventilation Syndrome Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Accord Healthcare Limited
Avet Pharmaceuticals Inc
Nostrum Laboratories Inc
Lannett Co Inc
Strides Pharma Science Limited
X Gen Pharmaceuticals Inc
ResMed
Koninklijke Philips NV
Hikma Pharmaceuticals
Lincare Holdings
Philips Respironics
Fisher & Paykel Healthcare Ltd
GE Healthcare
Medtronic PLC
Segment by Type
Oxygen Therapy
Non-invasive Mechanical Ventilation
Drug Therapy
Other
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Obesity Hypoventilation Syndrome Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Obesity Hypoventilation Syndrome Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oxygen Therapy
1.2.3 Non-invasive Mechanical Ventilation
1.2.4 Drug Therapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Obesity Hypoventilation Syndrome Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Obesity Hypoventilation Syndrome Treatment Market Perspective (2018-2029)
2.2 Obesity Hypoventilation Syndrome Treatment Growth Trends by Region
2.2.1 Global Obesity Hypoventilation Syndrome Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Obesity Hypoventilation Syndrome Treatment Historic Market Size by Region (2018-2023)
2.2.3 Obesity Hypoventilation Syndrome Treatment Forecasted Market Size by Region (2024-2029)
2.3 Obesity Hypoventilation Syndrome Treatment Market Dynamics
2.3.1 Obesity Hypoventilation Syndrome Treatment Industry Trends
2.3.2 Obesity Hypoventilation Syndrome Treatment Market Drivers
2.3.3 Obesity Hypoventilation Syndrome Treatment Market Challenges
2.3.4 Obesity Hypoventilation Syndrome Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Obesity Hypoventilation Syndrome Treatment Players by Revenue
3.1.1 Global Top Obesity Hypoventilation Syndrome Treatment Players by Revenue (2018-2023)
3.1.2 Global Obesity Hypoventilation Syndrome Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Obesity Hypoventilation Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Obesity Hypoventilation Syndrome Treatment Revenue
3.4 Global Obesity Hypoventilation Syndrome Treatment Market Concentration Ratio
3.4.1 Global Obesity Hypoventilation Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Obesity Hypoventilation Syndrome Treatment Revenue in 2022
3.5 Obesity Hypoventilation Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players Obesity Hypoventilation Syndrome Treatment Product Solution and Service
3.7 Date of Enter into Obesity Hypoventilation Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Obesity Hypoventilation Syndrome Treatment Breakdown Data by Type
4.1 Global Obesity Hypoventilation Syndrome Treatment Historic Market Size by Type (2018-2023)
4.2 Global Obesity Hypoventilation Syndrome Treatment Forecasted Market Size by Type (2024-2029)
5 Obesity Hypoventilation Syndrome Treatment Breakdown Data by Application
5.1 Global Obesity Hypoventilation Syndrome Treatment Historic Market Size by Application (2018-2023)
5.2 Global Obesity Hypoventilation Syndrome Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Obesity Hypoventilation Syndrome Treatment Market Size (2018-2029)
6.2 North America Obesity Hypoventilation Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Obesity Hypoventilation Syndrome Treatment Market Size by Country (2018-2023)
6.4 North America Obesity Hypoventilation Syndrome Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Obesity Hypoventilation Syndrome Treatment Market Size (2018-2029)
7.2 Europe Obesity Hypoventilation Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Obesity Hypoventilation Syndrome Treatment Market Size by Country (2018-2023)
7.4 Europe Obesity Hypoventilation Syndrome Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Obesity Hypoventilation Syndrome Treatment Market Size (2018-2029)
8.2 Asia-Pacific Obesity Hypoventilation Syndrome Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Obesity Hypoventilation Syndrome Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Obesity Hypoventilation Syndrome Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Obesity Hypoventilation Syndrome Treatment Market Size (2018-2029)
9.2 Latin America Obesity Hypoventilation Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Obesity Hypoventilation Syndrome Treatment Market Size by Country (2018-2023)
9.4 Latin America Obesity Hypoventilation Syndrome Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Size (2018-2029)
10.2 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Accord Healthcare Limited
11.1.1 Accord Healthcare Limited Company Detail
11.1.2 Accord Healthcare Limited Business Overview
11.1.3 Accord Healthcare Limited Obesity Hypoventilation Syndrome Treatment Introduction
11.1.4 Accord Healthcare Limited Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.1.5 Accord Healthcare Limited Recent Development
11.2 Avet Pharmaceuticals Inc
11.2.1 Avet Pharmaceuticals Inc Company Detail
11.2.2 Avet Pharmaceuticals Inc Business Overview
11.2.3 Avet Pharmaceuticals Inc Obesity Hypoventilation Syndrome Treatment Introduction
11.2.4 Avet Pharmaceuticals Inc Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.2.5 Avet Pharmaceuticals Inc Recent Development
11.3 Nostrum Laboratories Inc
11.3.1 Nostrum Laboratories Inc Company Detail
11.3.2 Nostrum Laboratories Inc Business Overview
11.3.3 Nostrum Laboratories Inc Obesity Hypoventilation Syndrome Treatment Introduction
11.3.4 Nostrum Laboratories Inc Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.3.5 Nostrum Laboratories Inc Recent Development
11.4 Lannett Co Inc
11.4.1 Lannett Co Inc Company Detail
11.4.2 Lannett Co Inc Business Overview
11.4.3 Lannett Co Inc Obesity Hypoventilation Syndrome Treatment Introduction
11.4.4 Lannett Co Inc Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.4.5 Lannett Co Inc Recent Development
11.5 Strides Pharma Science Limited
11.5.1 Strides Pharma Science Limited Company Detail
11.5.2 Strides Pharma Science Limited Business Overview
11.5.3 Strides Pharma Science Limited Obesity Hypoventilation Syndrome Treatment Introduction
11.5.4 Strides Pharma Science Limited Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.5.5 Strides Pharma Science Limited Recent Development
11.6 X Gen Pharmaceuticals Inc
11.6.1 X Gen Pharmaceuticals Inc Company Detail
11.6.2 X Gen Pharmaceuticals Inc Business Overview
11.6.3 X Gen Pharmaceuticals Inc Obesity Hypoventilation Syndrome Treatment Introduction
11.6.4 X Gen Pharmaceuticals Inc Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.6.5 X Gen Pharmaceuticals Inc Recent Development
11.7 ResMed
11.7.1 ResMed Company Detail
11.7.2 ResMed Business Overview
11.7.3 ResMed Obesity Hypoventilation Syndrome Treatment Introduction
11.7.4 ResMed Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.7.5 ResMed Recent Development
11.8 Koninklijke Philips NV
11.8.1 Koninklijke Philips NV Company Detail
11.8.2 Koninklijke Philips NV Business Overview
11.8.3 Koninklijke Philips NV Obesity Hypoventilation Syndrome Treatment Introduction
11.8.4 Koninklijke Philips NV Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.8.5 Koninklijke Philips NV Recent Development
11.9 Hikma Pharmaceuticals
11.9.1 Hikma Pharmaceuticals Company Detail
11.9.2 Hikma Pharmaceuticals Business Overview
11.9.3 Hikma Pharmaceuticals Obesity Hypoventilation Syndrome Treatment Introduction
11.9.4 Hikma Pharmaceuticals Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.9.5 Hikma Pharmaceuticals Recent Development
11.10 Lincare Holdings
11.10.1 Lincare Holdings Company Detail
11.10.2 Lincare Holdings Business Overview
11.10.3 Lincare Holdings Obesity Hypoventilation Syndrome Treatment Introduction
11.10.4 Lincare Holdings Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.10.5 Lincare Holdings Recent Development
11.11 Philips Respironics
11.11.1 Philips Respironics Company Detail
11.11.2 Philips Respironics Business Overview
11.11.3 Philips Respironics Obesity Hypoventilation Syndrome Treatment Introduction
11.11.4 Philips Respironics Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.11.5 Philips Respironics Recent Development
11.12 Fisher & Paykel Healthcare Ltd
11.12.1 Fisher & Paykel Healthcare Ltd Company Detail
11.12.2 Fisher & Paykel Healthcare Ltd Business Overview
11.12.3 Fisher & Paykel Healthcare Ltd Obesity Hypoventilation Syndrome Treatment Introduction
11.12.4 Fisher & Paykel Healthcare Ltd Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.12.5 Fisher & Paykel Healthcare Ltd Recent Development
11.13 GE Healthcare
11.13.1 GE Healthcare Company Detail
11.13.2 GE Healthcare Business Overview
11.13.3 GE Healthcare Obesity Hypoventilation Syndrome Treatment Introduction
11.13.4 GE Healthcare Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.13.5 GE Healthcare Recent Development
11.14 Medtronic PLC
11.14.1 Medtronic PLC Company Detail
11.14.2 Medtronic PLC Business Overview
11.14.3 Medtronic PLC Obesity Hypoventilation Syndrome Treatment Introduction
11.14.4 Medtronic PLC Revenue in Obesity Hypoventilation Syndrome Treatment Business (2018-2023)
11.14.5 Medtronic PLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
